SCHEMBL23932508

SCHEMBL23932508

ClCc1nc2ccc(Br)cc2o1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.46
KDM4E B2RXH2 2/20 0.46
AKR1B1 P15121 1/20 0.42
DAGLA Q9Y4D2 1/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
SOS1 Q07889 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
USP2 O75604 1/20 0.38
MAPK10 P53779 1/20 0.38
PIK3CG P48736 1/20 0.36
LMNA P02545 1/20 0.36
TP53 P04637 1/20 0.36
AAK1 Q2M2I8 1/20 0.35
MEN1 O00255 1/20 0.35
TSHR P16473 1/20 0.35
KMT2A Q03164 1/20 0.35
LOXL2 Q9Y4K0 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30041004 1.00 MAPT (0.46) MAPTKDM4EAKR1B1DAGLANPC1
SCHEMBL17097220 0.86 MAPT (0.51) MAPTKDM4EAKR1B1DAGLANPC1
SCHEMBL2323307 0.86 MEN1 (0.43) MAPTKDM4EAKR1B1NPC1RAB9A
SCHEMBL29994194 0.86 MEN1 (0.43) MAPTKDM4EAKR1B1NPC1RAB9A
SCHEMBL17955356 0.84 MAPT (0.47) MAPTKDM4EAKR1B1DAGLANPC1
SCHEMBL486127 0.80 PIK3CG (0.58) MAPTKDM4ENPC1RAB9ASOS1
SCHEMBL4288555 0.79 KDM4E (0.74) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL19746823 0.79 MAPT (0.46) MAPTKDM4EDAGLANPC1RAB9A
SCHEMBL9199893 0.79 ESR1 (0.53) MAPTKDM4ENPC1RAB9ASMN1; SMN2
SCHEMBL4055949 0.78 MAPT (0.58) MAPTKDM4ENPC1RAB9ASOS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2023-05-18 US disclosed
EP-4139291-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF Anima Biotech Inc. (US) 2023-03-01 EP disclosed
CN-115427404-A Collagen 1 translation inhibitors and methods of use thereof 艾尼莫生物科技公司 2022-12-02 CN disclosed
WO-2021216665-A9 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-12-02 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed
WO-2021216665-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF ANIMA BIOTECH INC. (US) 2021-10-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230150980-A1 COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF COL1A1, COL2A1, COL14A1 MAPT 3388/4885KDM4E 1980/4885AKR1B1 2459/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.